title: Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months.
abstract: BACKGROUND
  We have previously reported significant benefits of using enoxaparin, compared to tinzaparin, in the 7- and 30-day incidence of the composite triple end point of death, myocardial infarction (MI), or recurrent angina in patients with non-ST-segment elevation acute coronary syndromes (NSTACS). In the present study, we aimed to determine whether the observed benefits of enoxaparin were maintained beyond the early phase and report the results of the 6-m follow-up of patients in the EVET study.
  
  
  METHODS
  We recruited 438 patients with NSTACS. All patients received oral aspirin and were randomized to also receive enoxaparin, 100 IU/kg subcutaneously twice daily (equivalent to 1 mg/kg twice daily; n = 220), or tinzaparin, 175 IU/kg subcutaneously once daily (n = 218), for up to 7 days.
  
  
  RESULTS
  At 6 m, the incidence of the composite triple end point of death, MI, or recurrent angina was lower among patients receiving enoxaparin compared to those receiving tinzaparin (25.5% vs 44.0%, P < .001). A lower incidence of the secondary composite end point of death or MI was also found in the enoxaparin group compared to tinzaparin group (2.7% vs 6.9%, P = .046). The need for revascularization procedures was also lower in the enoxaparin group compared to tinzaparin group (23.2% vs 37.2%, P = .002).
  
  
  CONCLUSIONS
  In patients with NSTACS, enoxaparin significantly reduced the rates of recurrent ischemic events and therapeutic procedures in the short term, with sustained benefit at 6 m compared to tinzaparin.
authors.affiliation: Cardiology Division, Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece.
authors.forename: Christos
authors.initials: C
authors.lastname: Katsouras
authors.forename: Lampros K
authors.initials: LK
authors.lastname: Michalis
authors.forename: Nikos
authors.initials: N
authors.lastname: Papamichael
authors.forename: Kostas
authors.initials: K
authors.lastname: Adamides
authors.forename: Katerina K
authors.initials: KK
authors.lastname: Naka
authors.forename: Dimitris
authors.initials: D
authors.lastname: Nikas
authors.forename: John A
authors.initials: JA
authors.lastname: Goudevenos
authors.forename: Dimitris A
authors.initials: DA
authors.lastname: Sideris
mesh_terms: D000208:Acute Disease; D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy*; D004562:Electrocardiography; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D013577:Syndrome; D013997:Time Factors; D000078222:Tinzaparin
chemical_list: D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin